Jubilant Therapeutics announced the appointment of Daniel J. O'Connor as President & Chief Executive Officer.
Dan brings more than 30 years of leadership experience in biotechnology and oncology, with a proven track-record of creating value around differentiated, IP-rich platforms. Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation culminating in its successful acquisition.
Earlier in his career, Dan was instrumental at ImClone Systems, contributing to the clinical development, launch, and commercialization of a major oncology therapy while navigating complex intellectual property and inventorship challenges. He also served as CEO of Advaxis, a NASDAQ listed immune-oncology company, where he transformed the organization into a late-stage clinical enterprise, secured substantial growth capital, and forged strategic collaborations with leading pharmaceutical partners.
"We are delighted to welcome Dan as CEO of Jubilant Therapeutics Inc.," said Hari S Bhartia, Chairman, Jubilant Therapeutics Inc. "His extensive experience in building and scaling biopharmaceutical companies, combined with his deep expertise in oncology and strategic partnerships, will be instrumental in advancing our mission to deliver transformative therapies to patients."
On the occasion, Dan said, "I am honored to lead Jubilant Therapeutics Inc., a company dedicated to driving breakthrough innovation for cancers that are difficult to treat. I look forward to collaborating closely with our talented team to advance our mission and deliver meaningful value to patients, partners and stakeholders alike."
Dan holds a Juris Doctor (JD) from the Penn State Dickinson Law of The Pennsylvania State University and has served as an officer in the U.S. Marine Corps.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!